XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.3
Segment
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment Segment
The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of allocating resources and assessing financial performance. The Company has a single reporting unit associated with the development and commercialization of diagnostic tests and biopharmaceutical services. The accounting policies of the Company's single segment are the same as those described in the summary of significant accounting policies in Note 1, Organization, Description of Business and Summary of Significant Accounting Policies. The chief operating decision maker assesses performance of the Company's single segment and decides how to allocate resources based on consolidated net income. Under the current organizational structure, this measure is not discreetly available or required individually for any of the Company’s business activities and is only available at the consolidated level. The monitoring of budgeted versus actual results are used in assessing performance of the Company's single segment, allocating resources and in establishing management’s compensation. The Company's chief operating decision maker intends for all revenue generating activities to rely on cross-functional activities across the consolidated entity in order to operate. No individual besides the chief operating decision maker has been tasked with reviewing discreet operating results of the business activities, nor is there any intent to bifurcate the overall business review process to produce discreet operating results specific to any of the Company's business activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. Consolidated revenue does not include any inter-segment sales or transfers.
Information about reported segment revenue, measures of segment profit or loss, significant segment expenses and reconciliation to income from operations was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Revenue:
Testing revenue$127,756 $109,536 $357,328 $306,809 
Product revenue3,301 3,188 10,479 10,631 
Biopharmaceutical and other revenue815 3,136 8,702 9,692 
Total revenue131,872 115,860 376,509 327,132 
Cost of revenue:
Cost of testing revenue:
Laboratory supplies and reagents expense14,766 13,887 43,134 39,131 
Sample collection expense3,078 3,663 9,398 9,884 
Compensation expense6,273 5,743 17,906 16,097 
Other cost of testing revenue (1)6,456 2,797 14,017 9,122 
Allocation of facilities and IT expenses3,204 2,939 9,989 8,694 
Total cost of testing revenue33,777 29,029 94,444 82,928 
Cost of product revenue:
Product costs1,050 545 1,864 2,436 
License fees and royalties257 270 888 1,021 
Other cost of product revenue (2)1,672 750 2,980 2,372 
Allocation of facilities and IT expenses36 227 454 481 
Total cost of product revenue3,015 1,792 6,186 6,310 
Cost of biopharmaceutical and other revenue:
Compensation expense426 1,424 3,318 4,958 
Other cost of biopharmaceutical and other revenue (3)612 1,024 3,118 3,244 
Allocation of facilities and IT expenses53 664 925 1,560 
Total cost of biopharmaceutical and other revenue1,091 3,112 7,361 9,762 
Intangible asset amortization - cost of revenue2,707 2,917 7,959 8,741 
Gross profit91,282 79,010 260,559 219,391 
Operating expenses:
Research and development:
Compensation expense9,028 8,906 27,840 26,356 
Direct research and development expense3,512 5,479 10,946 14,596 
Other research and development expenses (4)1,586 1,338 5,278 4,195 
Allocation of facilities and IT expenses1,855 1,851 5,901 4,857 
Total research and development15,981 17,574 49,965 50,004 
Selling and marketing:
Compensation expense16,977 15,814 52,214 50,517 
Direct marketing expense1,376 1,427 3,564 4,613 
Other selling and marketing expenses (5)3,332 3,271 10,880 9,897 
Allocation of facilities and IT expenses2,770 2,100 7,567 5,583 
Total selling and marketing24,455 22,612 74,225 70,610 
General and administrative:
Compensation expense20,688 18,958 62,121 59,824 
Other general and administrative expenses (6)14,508 14,565 56,132 45,048 
Allocation of facilities and IT expenses(7,918)(7,781)(24,836)(21,175)
Total general and administrative27,278 25,742 93,417 83,697 
Impairment of assets— 185 20,505 614 
Intangible asset amortization - operating expenses622 880 1,865 2,499 
Other income, net4,057 (4,831)(6,985)(10,334)
Income tax (benefit) provision(248)1,693 2,363 3,276 
Net income$19,137 $15,155 $25,204 $19,025 
________________

(1)Other cost of testing revenue includes cytopathology services, depreciation and amortization and other expenses.
(2)Other cost of product revenue includes contract manufacturing fees, license fees and royalties, depreciation and amortization and other expenses.
(3)Other cost of biopharmaceutical and other revenue includes license fees and royalties, depreciation and amortization and other expenses.
(4)Other research and development expenses includes depreciation and amortization and other expenses.
(5)Other selling and marketing expenses includes travel, entertainment, conference and other expenses.
(6)Other general and administrative expenses includes professional fees, information technology expense, occupancy costs, depreciation and amortization, contingent consideration and other expenses.